HemaCare Corporation announced a distribution agreement with Charles River’s subsidiary, Vital River, to provide the scientific community in China with direct access to healthy and disease-state human primary cells. Vital River was chosen as a partner to expand China distribution because of HemaCare’s successful and growing global relationship with Charles River Laboratories. Under the terms of the agreement, Vital River will offer HemaCare’s full line of high-quality human primary cells and tissues to researchers in China.